Muyang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muyang Yang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Honglin Jin
NHC Key Laboratory of Tropical Disease Control School of Life Sciences and Medical Technology Hainan Medical University Haikou Hainan China
3 shared publications Deqiang Deng
NHC Key Laboratory of Tropical Disease Control School of Life Sciences and Medical Technology Hainan Medical University Haikou Hainan China
2 shared publications- Jonathan F. Lovell
Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, NY 14260, USA
2 shared publications Li Liu
College of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan P. R. China
2 shared publicationsXiujuan Shi
College of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan P. R. China
2 shared publicationsZihan Deng
College of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan P. R. China
2 shared publications
Latest Publications
- 4 September 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (60)
A Poly(lactic Acid)‐Porphyrin‐Cobalt Vaccine Adjuvant System Elicits Protein‐ or Peptide‐Specific Humoral and Cellular Immunity
There is growing interest in vaccine adjuvant systems that are scalable, adaptable, and capable of stimulating humoral and cellular immune responses with recombinant protein or synthetic peptide immunogens. In this study, we introduced a “plug‐and‐play” nanoadjuvant system consisting of poly(lactic acid)‐porphyrin‐cobalt ion co‐formulated with immunostimulatory saponin QS‐21 (PPCoQ). PPCoQ facilitated subunit vaccine assembly by coordinating antigens' polyhistidine tags with immobilized cobalt (Co 2+ ) within a porphyrin‐modified poly(lactic acid). Using the receptor‐binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) as a model antigen, the resulting nanovaccine, PPCoQ‐RBD, induced high levels of anti‐RBD antibodies in transgenic mice expressing human ACE2. Following viral challenge, immunized mice achieved a 99.7% clearance rate of the SARS‐CoV‐2 Omicron variant, demonstrating strong humoral and cellular immune responses. Additionally, PPCoQ‐RBD was compatible with nebulization‐based inhalation, which enhanced mucosal immunity, increased IgA antibody titers, and promoted the formation of abundant tissue‐resident memory T cells. A model T cell epitope (OVA) was formulated to evaluate cellular responses, generating PPCoQ‐OVA, which significantly inhibited B16‐OVA tumor growth. The PPCoQ vaccine adjuvant system is easy to produce and supports efficient antigen loading, lymph node targeting, lysosomal escape, and biocompatibility, and has broad prospects for application and clinical translation.
- 4 September 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (60)
A Poly(lactic Acid)‐Porphyrin‐Cobalt Vaccine Adjuvant System Elicits Protein‐ or Peptide‐Specific Humoral and Cellular Immunity
There is growing interest in vaccine adjuvant systems that are scalable, adaptable, and capable of stimulating humoral and cellular immune responses with recombinant protein or synthetic peptide immunogens. In this study, we introduced a “plug‐and‐play” nanoadjuvant system consisting of poly(lactic acid)‐porphyrin‐cobalt ion co‐formulated with immunostimulatory saponin QS‐21 (PPCoQ). PPCoQ facilitated subunit vaccine assembly by coordinating antigens' polyhistidine tags with immobilized cobalt (Co 2+ ) within a porphyrin‐modified poly(lactic acid). Using the receptor‐binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) as a model antigen, the resulting nanovaccine, PPCoQ‐RBD, induced high levels of anti‐RBD antibodies in transgenic mice expressing human ACE2. Following viral challenge, immunized mice achieved a 99.7% clearance rate of the SARS‐CoV‐2 Omicron variant, demonstrating strong humoral and cellular immune responses. Additionally, PPCoQ‐RBD was compatible with nebulization‐based inhalation, which enhanced mucosal immunity, increased IgA antibody titers, and promoted the formation of abundant tissue‐resident memory T cells. A model T cell epitope (OVA) was formulated to evaluate cellular responses, generating PPCoQ‐OVA, which significantly inhibited B16‐OVA tumor growth. The PPCoQ vaccine adjuvant system is easy to produce and supports efficient antigen loading, lymph node targeting, lysosomal escape, and biocompatibility, and has broad prospects for application and clinical translation.
- Open Access
- 18 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (31) , e74886
Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy
Pyroptosis, a form of immunogenic cell death, can remodel the immunosuppressive tumor microenvironment; however, its clinical translation is challenged by difficulties in targeted induction and biosafety concerns. In this study we discovered that geldanamycin (GA) can interacts specifically with arginine 207 (R207) in caspase‑3, and efficiently cleaved caspase‐3, significantly inducing high‐efficiency pyroptosis. Although high‐dose GA promoted pyroptosis and antitumor immunity, physiological toxicity and the induction of resistance mediated by immune checkpoints including PD‐L1 and CD47 limited therapeutic efficacy. To address this, we developed biomimetic dual‐targeting microparticles(MPs)functionalized with anti‐PD‐L1 and anti‐SIRPα nanobodies. This strategy synergized targeted pyroptosis induction with dual immune checkpoint blockade, achieving complete tumor regression, reduced physiological toxicity, and induced a potent effector immune response in murine cancer models, presenting a promising combinatorial approach for lung cancer immunotherapy.
- 18 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (31) , e74886
Open AccessPyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy
Pyroptosis, a form of immunogenic cell death, can remodel the immunosuppressive tumor microenvironment; however, its clinical translation is challenged by difficulties in targeted induction and biosafety concerns. In this study we discovered that geldanamycin (GA) can interacts specifically with arginine 207 (R207) in caspase‑3, and efficiently cleaved caspase‐3, significantly inducing high‐efficiency pyroptosis. Although high‐dose GA promoted pyroptosis and antitumor immunity, physiological toxicity and the induction of resistance mediated by immune checkpoints including PD‐L1 and CD47 limited therapeutic efficacy. To address this, we developed biomimetic dual‐targeting microparticles(MPs)functionalized with anti‐PD‐L1 and anti‐SIRPα nanobodies. This strategy synergized targeted pyroptosis induction with dual immune checkpoint blockade, achieving complete tumor regression, reduced physiological toxicity, and induced a potent effector immune response in murine cancer models, presenting a promising combinatorial approach for lung cancer immunotherapy.
- Open Access
- 28 March 2024
- Published by Wiley in Exploration
- Vol. 4 (6)
Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy
Because therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with relatively low toxicity, they have long been considered for application in repressing cancer progression. Traditional cancer vaccines containing a single or a few discrete tumor epitopes have failed in the clinic, possibly due to challenges in epitope selection, target downregulation, cancer cell heterogeneity, tumor microenvironment immunosuppression, or a lack of vaccine immunogenicity. Whole cancer cell or cancer membrane vaccines, which provide a rich source of antigens, are emerging as viable alternatives. Autologous and allogenic cellular cancer vaccines have been evaluated as clinical treatments. Tumor cell membranes (TCMs) are an intriguing antigen source, as they provide membrane‐accessible targets and, at the same time, serve as integrated carriers of vaccine adjuvants and other therapeutic agents. This review provides a summary of the properties and technologies for TCM cancer vaccines. Characteristics, categories, mechanisms, and preparation methods are discussed, as are the demonstrable additional benefits derived from combining TCM vaccines with chemotherapy, sonodynamic therapy, phototherapy, and oncolytic viruses. Further research in chemistry, biomedicine, cancer immunology, and bioinformatics to address current drawbacks could facilitate the clinical adoption of TCM vaccines.
- 28 March 2024
- Published by Wiley in Exploration
- Vol. 4 (6)
Open AccessTumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy
Because therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with relatively low toxicity, they have long been considered for application in repressing cancer progression. Traditional cancer vaccines containing a single or a few discrete tumor epitopes have failed in the clinic, possibly due to challenges in epitope selection, target downregulation, cancer cell heterogeneity, tumor microenvironment immunosuppression, or a lack of vaccine immunogenicity. Whole cancer cell or cancer membrane vaccines, which provide a rich source of antigens, are emerging as viable alternatives. Autologous and allogenic cellular cancer vaccines have been evaluated as clinical treatments. Tumor cell membranes (TCMs) are an intriguing antigen source, as they provide membrane‐accessible targets and, at the same time, serve as integrated carriers of vaccine adjuvants and other therapeutic agents. This review provides a summary of the properties and technologies for TCM cancer vaccines. Characteristics, categories, mechanisms, and preparation methods are discussed, as are the demonstrable additional benefits derived from combining TCM vaccines with chemotherapy, sonodynamic therapy, phototherapy, and oncolytic viruses. Further research in chemistry, biomedicine, cancer immunology, and bioinformatics to address current drawbacks could facilitate the clinical adoption of TCM vaccines.
- Open Access
- 1 January 2022
- Published by Shanghai Institute of Organic Chemistry in Chinese Journal of Organic Chemistry
- Vol. 42 (1) , 129-146
Progress in Selective Construction of Functional Aromatics with Cyclohexanone
- 1 January 2022
- Published by Shanghai Institute of Organic Chemistry in Chinese Journal of Organic Chemistry
- Vol. 42 (1) , 129-146
Open AccessProgress in Selective Construction of Functional Aromatics with Cyclohexanone